Summary of Clinical Use

KHK4083 has completed early clinical trial in patients with plaque psoriasis [5], ulcerative colitis [1,3] and atopic dermatitis [4]. It has been progressed to late stage clinical studies in atopic dermatitis.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT05651711	A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)	Phase 3 Interventional	Amgen
NCT05724199	A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)	Phase 3 Interventional	Amgen
NCT05882877	A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)	Phase 3 Interventional	Amgen